Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Corticodependent or Corticoresistant Brain Radionecrosis After Radiotherapy for Brain Metastases: a Multicentre Randomized, Controlled Double-blind Phase III Study, Comparing Bevacizumab Versus Placebo

NCT06471465 is registered in ClinicalTrials.gov with Institut Cancerologie de l'Ouest as lead sponsor.

NCT NCT06471465
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06471465 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Corticodependent or Corticoresistant Brain Radionecrosis After Radiotherapy for Brain Metastases: a Multicentre Randomized, Controlled Double-blind Phase III Study, Comparing Bevacizumab Versus Placebo
Lead sponsor
Institut Cancerologie de l'Ouest
Phase
Phase 3
Overall status
Recruiting
Start date
April 29, 2025
Completion date
August 31, 2030
Enrollment
84 (estimated)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

brain metastases, radionecrosis of brain